Augurex Life Sciences, Anti-14-3-3eta Multiplex Analyte Specific Reagents

Augurex Life Sciences has launched its anti-14-3-3eta Multiplex Analyte Specific reagents to support the development of diagnostic tests for axial spondyloarthritis, a debilitating form of inflammatory arthritis that targets the spine and sacroiliac joints. New Day Diagnostics developed a first-in-class diagnostic test for the ailment using the reagents and offers the test through physician order, Vancouver, British Columbia-based Augurex said. The further development of additional tests using the reagents will address a "critical" need for tools for the early diagnosis of axial spondyloarthritis, it added.